Skip to content


The Pharmasyntez Group is the leading national manufacturer of pharmaceuticals for the treatment of socially significant diseases.


The Company is one of the largest Russian pharmaceutical industry investors. The cumulative volume of investments in projects to be completed by 2024 is over 23 bln rubles.

Pharmasyntez-Nord, Saint Petersburg

2021: Facility for research and production of biological drugs for the treatment of cancer, autoimmune diseases, and endocrine diseases.

2021: Department for the production of Gam-COVID-Vac (Sputnik Light) vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.

Pharmasyntez-Tyumen, Tyumen

2021: Plant for hormonal drug production.

2024: Plant for production of heart disease drugs.

East-Pharm, Ussuriysk

2023: Plant for parenteral nutrition production in the Kaluga Special Economic Zone.

BratskChemSyntez, Bratsk

2023: Building for general APIs large scale production with an output of 1000 tons per year.

The company employs
highly skilled professionals


There are two innovation drugs:

Drug candidate:

License Agreements

Pharmasyntez against COVID -19

Production of large-scale batches of the drugs for the treatment of the new coronavirus infection:

A full cycle production including the production of Remdesivir and Favipiravir APIs is carried out at the BratskChemSyntez plant in Bratsk, Irkutsk Region, Russia.

* Included in the treatment regimen for the new coronavirus infection by the Ministry of Healthcare of the Russian Federation


Irkutsk Office:

184, Rosa Luxemburg St., Irkutsk, Russia, 664040

Tel.: +7 3952 550355

Moscow Office:

12, Presnenskaya naberezhnaya, Federation Tower (West), 42th floor, Moscow, Russia, 123100

Tel.: +7 495 7505437

Скачать буклет